Cancer Research Landon Prizes for Basic and Translational Cancer Research AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Debes, J. D.
Right arrow Articles by Tindall, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Debes, J. D.
Right arrow Articles by Tindall, D. J.
[Cancer Research 62, 5632-5636, October 15, 2002]
© 2002 American Association for Cancer Research

Advances in Brief

p300 Mediates Androgen-independent Transactivation of the Androgen Receptor by Interleukin 61

Jose D. Debes, Lucy J. Schmidt, Haojie Huang and Donald J. Tindall2

Departments of Urology [J. D. D., L. J. S., H. H., D. J. T.], Biochemistry, and Molecular Biology [D. J. T.], Mayo Clinic and Foundation, Rochester, Minnesota 55905

Prostate cancer (PCa) begins as an androgen-dependent tumor that will eventually progress to an androgen-independent stage after androgen ablation. Although little is understood about this transition to androgen independence, the androgen receptor (AR) appears to be involved. The coactivator p300 has been shown to interact with the AR during its androgen-dependent transactivation. We show that p300 is involved downstream of the mitogen-activated protein kinase pathway during transactivation of the AR by interleukin-6 (IL-6). Furthermore, we demonstrate that sequestration of p300 with E1A inhibits the IL-6-dependent transactivation of the AR, and that increasing amounts of p300 reverse this inhibition. A mutant p300 that lacks histone acetyltransferase (HAT) activity did not reverse E1A-mediated inhibition. By using small-interference RNA designed to target p300 transcripts, we demonstrate that, after silencing p300, there was no induction of AR activity by IL-6. These findings reveal a unique role for p300 and its HAT activity, indicating that it is necessary for the ligand-independent transactivation of the AR in androgen-independent PCa cells.




This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
N. K. Mukhopadhyay, B. Cinar, L. Mukhopadhyay, M. Lutchman, A. S. Ferdinand, J. Kim, L. W. K. Chung, R. M. Adam, S. K. Ray, A. B. Leiter, et al.
The Zinc Finger Protein Ras-Responsive Element Binding Protein-1 Is a Coregulator of the Androgen Receptor: Implications for the Role of the Ras Pathway in Enhancing Androgenic Signaling in Prostate Cancer
Mol. Endocrinol., September 1, 2007; 21(9): 2056 - 2070.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C.-C. Yang, Y.-C. Wang, S. Wei, L.-F. Lin, C.-S. Chen, C.-C. Lee, C.-C. Lin, and C.-S. Chen
Peroxisome Proliferator-Activated Receptor {gamma}-Independent Suppression of Androgen Receptor Expression by Troglitazone Mechanism and Pharmacologic Exploitation
Cancer Res., April 1, 2007; 67(7): 3229 - 3238.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. V. Heemers, T. J. Sebo, J. D. Debes, K. M. Regan, K. A. Raclaw, L. M. Murphy, A. Hobisch, Z. Culig, and D. J. Tindall
Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells
Cancer Res., April 1, 2007; 67(7): 3422 - 3430.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
R. Jasavala, H. Martinez, J. Thumar, A. Andaya, A.-C. Gingras, J. K. Eng, R. Aebersold, D. K. Han, and M. E. Wright
Identification of Putative Androgen Receptor Interaction Protein Modules: Cytoskeleton and Endosomes Modulate Androgen Receptor Signaling in Prostate Cancer Cells
Mol. Cell. Proteomics, February 1, 2007; 6(2): 252 - 271.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
I. Bellezza, H. Neuwirt, C. Nemes, I. T. Cavarretta, M. Puhr, H. Steiner, A. Minelli, G. Bartsch, F. Offner, A. Hobisch, et al.
Suppressor of Cytokine Signaling-3 Antagonizes cAMP Effects on Proliferation and Apoptosis and Is Expressed in Human Prostate Cancer
Am. J. Pathol., December 1, 2006; 169(6): 2199 - 2208.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
P Singh, A Uzgare, I Litvinov, S R Denmeade, and J T Isaacs
Combinatorial androgen receptor targeted therapy for prostate cancer.
Endocr. Relat. Cancer, September 1, 2006; 13(3): 653 - 666.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
I. R. Logan, L. Gaughan, S. R. C. McCracken, V. Sapountzi, H. Y. Leung, and C. N. Robson
Human PIRH2 Enhances Androgen Receptor Signaling through Inhibition of Histone Deacetylase 1 and Is Overexpressed in Prostate Cancer.
Mol. Cell. Biol., September 1, 2006; 26(17): 6502 - 6510.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
A. Hoffmann, T. Barz, and D. Spengler
Multitasking C2H2 Zinc Fingers Link Zac DNA Binding to Coordinated Regulation of p300-Histone Acetyltransferase Activity.
Mol. Cell. Biol., July 1, 2006; 26(14): 5544 - 5557.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Wallner, J. Dai, J. Escara-Wilke, J. Zhang, Z. Yao, Y. Lu, M. Trikha, J. A. Nemeth, M. H. Zaki, and E. T. Keller
Inhibition of Interleukin-6 with CNTO328, an Anti-Interleukin-6 Monoclonal Antibody, Inhibits Conversion of Androgen-Dependent Prostate Cancer to an Androgen-Independent Phenotype in Orchiectomized Mice.
Cancer Res., March 15, 2006; 66(6): 3087 - 3095.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. D. Debes, B. Comuzzi, L. J. Schmidt, S. M. Dehm, Z. Culig, and D. J. Tindall
p300 Regulates Androgen Receptor-Independent Expression of Prostate-Specific Antigen in Prostate Cancer Cells Treated Chronically with Interleukin-6
Cancer Res., July 1, 2005; 65(13): 5965 - 5973.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
Z Culig, H Steiner, G Bartsch, and A Hobisch
Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours
Endocr. Relat. Cancer, June 1, 2005; 12(2): 229 - 244.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D.E. Clark, T.M. Errington, J.A. Smith, H.F. Frierson Jr., M.J. Weber, and D.A. Lannigan
The Serine/Threonine Protein Kinase, p90 Ribosomal S6 Kinase, Is an Important Regulator of Prostate Cancer Cell Proliferation
Cancer Res., April 15, 2005; 65(8): 3108 - 3116.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
J Kim, L Jia, M R Stallcup, and G A Coetzee
The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus
J. Mol. Endocrinol., February 1, 2005; 34(1): 107 - 118.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. D. Debes, T. J. Sebo, H. V. Heemers, B. R. Kipp, D. A. L. Haugen, C. M. Lohse, and D. J. Tindall
p300 Modulates Nuclear Morphology in Prostate Cancer
Cancer Res., February 1, 2005; 65(3): 708 - 712.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Renal Physiol.Home page
L. Pan, Y. Wang, C. A. Jones, S. T. Glenn, H. Baumann, and K. W. Gross
Enhancer-dependent inhibition of mouse renin transcription by inflammatory cytokines
Am J Physiol Renal Physiol, January 1, 2005; 288(1): F117 - F124.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
C. A. Heinlein and C. Chang
Androgen Receptor in Prostate Cancer
Endocr. Rev., April 1, 2004; 25(2): 276 - 308.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
L. Jia, C. S-Y. Choong, C. Ricciardelli, J. Kim, W. D. Tilley, and G. A Coetzee
Androgen Receptor Signaling: Mechanism of Interleukin-6 Inhibition
Cancer Res., April 1, 2004; 64(7): 2619 - 2626.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Rahman, H. Miyamoto, and C. Chang
Androgen Receptor Coregulators in Prostate Cancer: Mechanisms and Clinical Implications
Clin. Cancer Res., April 1, 2004; 10(7): 2208 - 2219.
[Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
K. M. Sakamoto, K. B. Kim, R. Verma, A. Ransick, B. Stein, C. M. Crews, and R. J. Deshaies
Development of Protacs to Target Cancer-promoting Proteins for Ubiquitination and Degradation
Mol. Cell. Proteomics, December 1, 2003; 2(12): 1350 - 1358.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. D. Debes, T. J. Sebo, C. M. Lohse, L. M. Murphy, D. A. L. Haugen, and D. J. Tindall
p300 in Prostate Cancer Proliferation and Progression
Cancer Res., November 15, 2003; 63(22): 7638 - 7640.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. E. Bakin, D. Gioeli, R. A. Sikes, E. A. Bissonette, and M. J. Weber
Constitutive Activation of the Ras/Mitogen-activated Protein Kinase Signaling Pathway Promotes Androgen Hypersensitivity in LNCaP Prostate Cancer Cells
Cancer Res., April 15, 2003; 63(8): 1981 - 1989.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
L. Jia, J. Kim, H. Shen, P. E. Clark, W. D. Tilley, and G. A. Coetzee
Androgen Receptor Activity at the Prostate Specific Antigen Locus: Steroidal and Non-Steroidal Mechanisms
Mol. Cancer Res., March 1, 2003; 1(5): 385 - 392.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.